We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Diagnostic Value of Serum CHI3L1 in Hepatocellular Carcinoma Explored

By LabMedica International staff writers
Posted on 02 Feb 2022
Print article
Image: The Proprium Fibro-CHI Diagnostic ELISA Kit for the quantification of Chitinase 3-Like 1 (CHI3L1) in serum and plasma (Photo courtesy of Proprium Biotech Company Limited)
Image: The Proprium Fibro-CHI Diagnostic ELISA Kit for the quantification of Chitinase 3-Like 1 (CHI3L1) in serum and plasma (Photo courtesy of Proprium Biotech Company Limited)
Primary liver cancer is the sixth diagnosed cancer and the fourth cause of cancer-related death worldwide. Hepatocellular carcinoma (HCC) is the major pathological category and comprises a 75%–85% incidence of primary liver cancer cases.

Chitinase 3-like protein 1 (CHI3L1) belongs to the family 18-glycosyl hydrolase but lacks chitinolytic activity. CHI3L1 has shown better performance in diagnosing liver fibrosis than other noninvasive methods in chronic hepatitis B patients.

Scientists specializing in Hepatology at the University of Chinese Academy of Sciences (Ningbo, China) enrolled in a retrospective study the following: matched age and gender subjects, 40 patients with liver cirrhosis, 40 patients with chronic hepatitis, and 40 healthy subjects were enrolled in the control group. The data was collected from December 2018 to April 2020. The serum CHI3L1 level was determined by enzyme-linked immunosorbent assay (ELISA) and in a blinded manner.

The CHI3L1 ELISA Kit was produced by Proprium Biotech Company Limited, (Hangzhou, China). The expression level of CHI3L1 was detected once the subjects first visit the clinic or admit to hospital. The follow-up time was 8 to 22 months. During the follow-up period, laboratory monitoring was performed every 3 to 6 months, including routine blood chemistry tests and imaging studies using computed tomography (CT) or magnetic resonance imaging (MRI) to monitor disease status. The clinicopathological data of 50 paired HCC and adjacent non-tumor tissues as well as 278 unpaired HCC tissues, and the relative expression levels of CHI3L1 was studied.

The investigators reported that the median serum level of CHI3L1 in the HCC group was 168.84 ng/mL (95%CI = 96.24, 322.61 ng/mL), which was significantly higher than the median serum level of CHI3L1 in the control group, median = 71.36 ng/mL (95% CI = 48.63, 114.77 ng/mL). Serum CHI3L1 level was closely correlated with serum α-fetoprotein (AFP) level, tumor-node-metastasis (TNM) stage, Child-Pugh stage, the maximum diameter of tumor, and presence of liver cirrhosis, but there was no significant correlation between gender and age.

The patients with high AFP level (>400 ng/L), TNM III + IV stage, large tumor diameter, liver cirrhosis, and Child-Pugh B + C had higher serum CHI3L1 levels. The overall survival (OS) rate of patients with high expression of CHI3L1 was significantly lower than that of patients with low expression of CHI3L1. Combining the serum CHI3L1 and α-fetoprotein (AFP) by a binary logistic regression model can increase the diagnostic sensitivity to 97.5%. Multivariate Cox regression analysis indicated that CHI3L1 is an independent prognostic factor in patients with HCC.

The authors concluded that they compared the difference of serum CHI3L1 between the HCC group and the control group, analyzed the diagnostic performance of CHI3L1 for HCC, and evaluated the prognostic power of serum CHI3L1 in HCC patients. The results showed that serum CHI3L1 can help to increase diagnostic power and evaluate prognosis for HCC patients. The study was published on January 16, 2022 in the Journal of Clinical Laboratory Analysis.

Related Links:
University of Chinese Academy of Sciences
Proprium Biotech Company Limited


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Piezoelectric Micropump
Disc Pump

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.